Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123565442 | 12356544 | 2 | F | 20160704 | 20160511 | 20160706 | EXP | PHHY2016PL062535 | NOVARTIS | 67.00 | YR | F | Y | 0.00000 | 20160706 | CN | COUNTRY NOT SPECIFIED | PL |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123565442 | 12356544 | 1 | PS | LAPATINIB | LAPATINIB | 1 | Unknown | 1250 MG, QD (5 TABLETS AS A SINGLE DOSE) | 22059 | 1250 | MG | TABLET | QD | ||||||
| 123565442 | 12356544 | 2 | SS | CAPECITABINE. | CAPECITABINE | 1 | Unknown | 2000 MG/M2, QD (IN TWO DIVIDED DOSES FOR THE FIRST 14 DAYS OF TREATMENT IN 21 DAY CYCLE) | 0 | 2000 | MG/M**2 | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 123565442 | 12356544 | 1 | HER-2 positive breast cancer |
| 123565442 | 12356544 | 2 | HER-2 positive breast cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 123565442 | 12356544 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 123565442 | 12356544 | HER-2 positive breast cancer | |
| 123565442 | 12356544 | Malignant neoplasm progression | |
| 123565442 | 12356544 | Neutropenia | |
| 123565442 | 12356544 | Thrombocytopenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |